Literature DB >> 26684088

Precision medicine: an opportunity for a paradigm shift in veterinary medicine.

K C Kent Lloyd, Chand Khanna, William Hendricks, Jeffrey Trent, Michael Kotlikoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26684088      PMCID： PMC4996120          DOI： 10.2460/javma.248.1.45

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN： 0003-1488            Impact factor:   1.936


× No keyword cloud information.
  21 in total

1.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Authors:  Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases.

Authors:  Kornelia Neveling; Ilse Feenstra; Christian Gilissen; Lies H Hoefsloot; Erik-Jan Kamsteeg; Arjen R Mensenkamp; Richard J T Rodenburg; Helger G Yntema; Liesbeth Spruijt; Sascha Vermeer; Tuula Rinne; Koen L van Gassen; Danielle Bodmer; Dorien Lugtenberg; Rick de Reuver; Wendy Buijsman; Ronny C Derks; Nienke Wieskamp; Bert van den Heuvel; Marjolijn J L Ligtenberg; Hannie Kremer; David A Koolen; Bart P C van de Warrenburg; Frans P M Cremers; Carlo L M Marcelis; Jan A M Smeitink; Saskia B Wortmann; Wendy A G van Zelst-Stams; Joris A Veltman; Han G Brunner; Hans Scheffer; Marcel R Nelen
Journal:  Hum Mutat       Date:  2013-10-18       Impact factor: 4.878

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

Review 4.  Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.

Authors:  Michael Röring; Tilman Brummer
Journal:  Crit Rev Oncog       Date:  2012

5.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

6.  Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach.

Authors:  Ian S Hagemann; Patrick K O'Neill; Ivan Erill; John D Pfeifer
Journal:  Cancer Genet       Date:  2015-05-29

7.  Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Authors:  Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Saundra S Buys; Beth Crawford; Susan Friedman; Judy E Garber; Carolyn Horton; Virginia Kaklamani; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Boris Pasche; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Georgia L Wiesner; Mary A Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

8.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

10.  Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.

Authors:  Melissa Paoloni; Craig Webb; Christina Mazcko; David Cherba; William Hendricks; Susan Lana; E J Ehrhart; Brad Charles; Heather Fehling; Leena Kumar; David Vail; Michael Henson; Michael Childress; Barbara Kitchell; Christopher Kingsley; Seungchan Kim; Mark Neff; Barbara Davis; Chand Khanna; Jeffrey Trent
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240
View more
  1 in total

1.  Constructing and analysing dynamic models with modelbase v1.2.3: a software update.

Authors:  Marvin van Aalst; Oliver Ebenhöh; Anna Matuszyńska
Journal:  BMC Bioinformatics       Date:  2021-04-20       Impact factor: 3.169
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.